Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7.
Dhruv MahttaMichelle T LeeDavid J RamseyJulia M AkeroydChayakrit KrittanawongSafi U KhanPreetika SinhMahboob AlamKirk N GarrattRichard S SchofieldChristie M BallantyneLaura A PetersenSalim S ViraniPublished in: Cardiovascular drugs and therapy (2021)
There is suboptimal use and significant facility-level variation in the use of statin and antiplatelet therapy among patients with premature and extremely premature ASCVD. Interventions are needed to optimize care and minimize variation among young ASCVD patients.
Keyphrases
- cardiovascular disease
- antiplatelet therapy
- end stage renal disease
- acute coronary syndrome
- percutaneous coronary intervention
- ejection fraction
- newly diagnosed
- chronic kidney disease
- type diabetes
- coronary artery disease
- physical activity
- peritoneal dialysis
- cardiovascular events
- adipose tissue
- metabolic syndrome
- cardiovascular risk factors
- skeletal muscle
- glycemic control
- insulin resistance
- atrial fibrillation